Trial Profile
A Randomised Double Blind, Multiple Dose, Pharmacokinetic and Safety Study of SENS 401 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Arazasetron (Primary)
- Indications Hearing loss; Sensorineural hearing loss
- Focus Adverse reactions
- 29 Jun 2018 According to a Sensorion media release, data from this trial were presented at the 15th International Conference on Cochlear Implants and Other Implantable Auditory Technologies (Ci2018).
- 14 Feb 2018 According to a Sensorion media release, results were presented at the Association for Research in Otolaryngologys (ARO) 41st Annual MidWinter Meeting.
- 18 Oct 2017 Status changed from active, no longer recruiting to completed, according to a Sensorion media release.